Dawnrays Pharmaceutical (Holdings) Ltd
02348
Company Profile
Business description
Dawnrays Pharmaceutical (Holdings) Ltd is a drug manufacturing company. The company operates two segments, Manufacture and sale of finished drugs and Manufacture and sale of intermediates and bulk medicines. The revenue is derived from the Finished Drugs segment. Nearly all of the company's sales are generated in Mainland China. It utilizes strategic partnerships as a component of its international strategies. The company is open to exploring potential acquisitions as a component of its overall growth plan.
Contact
338 Hennessy Road
Units 3001-02, 30th Floor, CNT Tower
Wanchai, North Sea Centre
Hong Kong
HKGT: +852 21119708
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
1,081
Stocks News & Analysis
stocks
Tesla: Reported China divestiture plan could clear path for SpaceX merger
Media report says Tesla is exploring divestiture plans to ease regulatory approval of a Tesla-SpaceX merger.
stocks
This onetime AI market darling is now surprisingly undervalued
This AI leader qualifies as a GARP stock today.
stocks
Undervalued ASX miner hits production homerun
Record volumes, lower costs and reduced debt underpin a stronger earnings outlook for ASX miner.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,137.00 | 70.20 | -0.76% |
| CAC 40 | 8,509.64 | 24.00 | 0.28% |
| DAX 40 | 25,629.24 | 17.21 | 0.07% |
| Dow JONES (US) | 52,485.03 | 276.97 | 0.53% |
| FTSE 100 | 10,868.05 | 29.22 | -0.27% |
| HKSE | 25,884.43 | 25.55 | 0.10% |
| NASDAQ | 25,373.85 | 251.68 | 1.00% |
| Nikkei 225 | 64,362.02 | 2,494.59 | 4.03% |
| NZX 50 Index | 13,699.28 | 63.50 | -0.46% |
| S&P 500 | 7,489.72 | 52.09 | 0.70% |
| S&P/ASX 200 | 8,976.80 | 73.10 | -0.81% |
| SSE Composite Index | 3,832.26 | 27.57 | 0.72% |